×

Curis to Release First Quarter 2015 Financial Results and Hold Conference Call on May 7, 2015

LEXINGTON, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will release its first quarter 2015 financial results on Thursday, May 7, 2015, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT to review: (i) its proprietary clinical development programs, including CUDC-907, (ii) programs under its collaboration with Aurigene, and (iii) its partnered program, Erivedge® (vismodegib). The Company's management will also review its financial results as of and for the first quarter ended March 31, 2015.

To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations, shortly before 8:30 A.M. EDT. The conference ID number is 75846737. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section.

About Curis, Inc.

Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis' pipeline of drug candidates includes CUDC-907, a dual HDAC and PI3K inhibitor, CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-305, an oral HSP90 inhibitor. Curis is engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. Curis is also party to a collaboration agreement with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge®, the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.

CONTACT: For More Information: Mani Mohindru, Ph.D. Senior Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 mmohindru@curis.com Media Contact: David Schull Russo Partners 212-845-4271 david.schull@russopartnersllc.com

Source:Curis, Inc.